Hanmi Unveils New EP300 Anticancer Degrader and Expands Biotech Pipeline

South Korea’s Hanmi Pharmaceutical has unveiled promising preclinical results for its new EP300-selective degrader, an innovative anticancer therapy designed to target and destroy cancer cells dependent on the EP300 protein. The data were presented at an international cancer research conference held in Boston, highlighting the company’s growing leadership in next-generation oncology drug discovery.

Diversified Research Portfolio

Alongside the EP300 degrader, Hanmi showcased several other early-stage drug candidates, including an SOS1-KRAS interaction inhibitor, STING mRNA anticancer therapy, p53-mRNA-based treatment, and a YAP/TAZ-TEAD inhibitor. These developments underscore Hanmi’s strategy to advance multiple precision oncology programs that leverage targeted degradation, mRNA technologies, and pathway-specific inhibition to treat difficult-to-target cancers.

Strengthening Global Vaccine Innovation
In related developments, SK bioscience announced progress in its collaboration with the Hallemann Institute, a global vaccine research body. Following their 2023 joint development agreement on a next-generation Zaire Ebola vaccine, the partners are now exploring new vaccine platform technologies for infectious disease preparedness, focusing on process development, technology transfer, and future commercialization efforts.